• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在英国进行的一项登记研究，对象为先前接受过三种或更多种包括蛋白酶体抑制剂、免疫调节剂和CD38靶向单克隆抗体疗法在内的先前疗法的复发或难治性多发性骨髓瘤患者。

A registry study of relapsed or refractory multiple myeloma pre-exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38-targeted monoclonal antibody therapy in England.

作者信息

Elsada Ahmed, Zalin-Miller Amy, Knott Craig, Caravotas Leonidas

机构信息

Janssen UK High Wycombe UK.

Health Data Insight CIC Cambridge UK.

出版信息

EJHaem. 2021 Jun 10;2(3):493-497. doi: 10.1002/jha2.214. eCollection 2021 Aug.

DOI:10.1002/jha2.214
PMID:35844690
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9175886/
Abstract

Some patients with multiple myeloma are receiving treatment in clinical practice in England after prior exposure to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. We investigated the characteristics of these patients, their outcomes, and the salvage therapies they received using the national cancer registry for England and linked healthcare data. After a median follow-up time of 6.4 months from , median overall survival and time to next treatment were 8.2 and 5.3 months, respectively. This real-world data provide useful clinical insight into a little-studied patient population and highlight the poor outcomes in the UK setting.

摘要

在英国的临床实践中，一些多发性骨髓瘤患者在先前接触过蛋白酶体抑制剂、免疫调节剂和抗CD38单克隆抗体后仍在接受治疗。我们利用英格兰国家癌症登记处和相关医疗保健数据，调查了这些患者的特征、治疗结果以及他们接受的挽救治疗方法。从……起，中位随访时间为6.4个月，中位总生存期和至下次治疗时间分别为8.2个月和5.3个月。这些真实世界的数据为一个研究较少的患者群体提供了有用的临床见解，并突出了英国患者群体预后不佳的情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f47/9175886/2607ae63015f/JHA2-2-493-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f47/9175886/2607ae63015f/JHA2-2-493-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f47/9175886/2607ae63015f/JHA2-2-493-g001.jpg

相似文献

1
A registry study of relapsed or refractory multiple myeloma pre-exposed to three or more prior therapies including a proteasome inhibitor, an immunomodulatory agent and CD38-targeted monoclonal antibody therapy in England.在英国进行的一项登记研究，对象为先前接受过三种或更多种包括蛋白酶体抑制剂、免疫调节剂和CD38靶向单克隆抗体疗法在内的先前疗法的复发或难治性多发性骨髓瘤患者。
EJHaem. 2021 Jun 10;2(3):493-497. doi: 10.1002/jha2.214. eCollection 2021 Aug.
2
Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in Japan.日本复发/难治性多发性骨髓瘤三联疗法暴露患者的治疗模式及结局
Future Oncol. 2022 Nov 4. doi: 10.2217/fon-2022-0846.
3
Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry.接受过三种或更多种既往治疗的复发/难治性多发性骨髓瘤患者的真实世界结局：来自澳大利亚和新西兰骨髓瘤和相关疾病登记处的分析。
Intern Med J. 2024 May;54(5):773-778. doi: 10.1111/imj.16277. Epub 2023 Dec 27.
4
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A Podcast.真实世界数据下复发/难治性多发性骨髓瘤的治疗选择：ASH 2023 年会 podcast 关键数据
Adv Ther. 2024 Aug;41(8):3017-3027. doi: 10.1007/s12325-024-02842-9. Epub 2024 Apr 20.
5
Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study.双药难治和三药难治多发性骨髓瘤患者的治疗模式和总生存：一项美国电子健康记录数据库研究。
Leuk Lymphoma. 2023 Feb;64(2):398-406. doi: 10.1080/10428194.2022.2140284. Epub 2022 Nov 21.
6
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.单药达雷妥尤单抗治疗复发/难治性多发性骨髓瘤的真实世界回顾性单中心研究。
Ann Hematol. 2019 Jun;98(6):1435-1440. doi: 10.1007/s00277-019-03655-5. Epub 2019 Mar 14.
7
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma.cilta-cabtagene autoleucel在CARTITUDE-1研究中与医师选择的疗法在Flatiron Health多发性骨髓瘤队列登记中治疗复发或难治性多发性骨髓瘤患者的比较疗效。
EJHaem. 2021 Dec 10;3(1):97-108. doi: 10.1002/jha2.312. eCollection 2022 Feb.
8
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.在中国复发/难治性多发性骨髓瘤患者中，塞来昔布联合低剂量地塞米松治疗既往接受免疫调节剂和蛋白酶体抑制剂治疗的患者（MARCH）：一项 II 期、单臂研究。
BMC Med. 2022 Apr 5;20(1):108. doi: 10.1186/s12916-022-02305-4.
9
Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study.三药暴露复发/难治性多发性骨髓瘤患者的治疗模式和结局：来自多国 ITEMISE 研究的结果。
Clin Ther. 2021 Nov;43(11):1983-1996.e3. doi: 10.1016/j.clinthera.2021.09.013. Epub 2021 Nov 2.
10
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.真实世界中抗 CD38 抗体治疗（包括三药难治）多发性骨髓瘤患者结局的数据：来自加拿大骨髓瘤研究组（CMRG）数据库的多机构报告。
Blood Cancer J. 2023 Dec 8;13(1):181. doi: 10.1038/s41408-023-00946-z.

引用本文的文献

1
Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma.在英国，elranatamab与现实世界中针对三重暴露复发和难治性多发性骨髓瘤的治疗结果比较。
BMC Cancer. 2025 Jul 25;25(1):1219. doi: 10.1186/s12885-025-14624-9.
2
Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma, Including Those Who are Triple-Class Exposed: A Retrospective Cohort Study in England Using National Cancer Registry Data.多发性骨髓瘤患者的特征、治疗模式及预后，包括那些接受过三类药物治疗的患者：一项利用国家癌症登记数据在英格兰开展的回顾性队列研究。
EJHaem. 2025 Jun 26;6(4):e70064. doi: 10.1002/jha2.70064. eCollection 2025 Aug.
3

本文引用的文献

1
A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple-myeloma patients.一项针对硼替佐米、每周一次硼替佐米和地塞米松在多发性骨髓瘤患者高度预处理人群中的真实世界研究。
Br J Haematol. 2020 Dec;191(5):927-930. doi: 10.1111/bjh.17076. Epub 2020 Sep 10.
2
Treatment Options for Triple-class Refractory Multiple Myeloma.三药难治性多发性骨髓瘤的治疗选择。
Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):1-7. doi: 10.1016/j.clml.2019.09.621. Epub 2019 Oct 9.
3
Data Resource Profile: The Systemic Anti-Cancer Therapy (SACT) dataset.
Allogeneic Stem Cell Transplantation in Multiple Myeloma: Risk Factors and Outcomes in the Era of New Therapeutic Options-A Single-Center Experience.
多发性骨髓瘤的异基因干细胞移植：新治疗选择时代的风险因素与结局——单中心经验
Cancers (Basel). 2023 Dec 7;15(24):5738. doi: 10.3390/cancers15245738.
数据资源简介：全身抗癌治疗（SACT）数据集。
Int J Epidemiol. 2020 Feb 1;49(1):15-15l. doi: 10.1093/ije/dyz137.
4
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗用于新诊断多发性骨髓瘤患者自体造血干细胞移植前后（CASSIOPEIA）：一项随机、开放标签、3 期研究。
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
5
Data Resource Profile: National Cancer Registration Dataset in England.数据资源简介：英格兰国家癌症登记数据集
Int J Epidemiol. 2020 Feb 1;49(1):16-16h. doi: 10.1093/ije/dyz076.
6
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.对 CD38 靶向单克隆抗体治疗耐药的多发性骨髓瘤患者的结局。
Leukemia. 2019 Sep;33(9):2266-2275. doi: 10.1038/s41375-019-0435-7. Epub 2019 Mar 11.
7
Data Resource Profile: Hospital Episode Statistics Admitted Patient Care (HES APC).数据资源简介：医院事件统计入院患者护理（HES APC）
Int J Epidemiol. 2017 Aug 1;46(4):1093-1093i. doi: 10.1093/ije/dyx015.
8
Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.对接受过≥3线既往治疗（包括蛋白酶体抑制剂（PI）和免疫调节药物（IMiD），或对PI和IMiD双重难治）的多发性骨髓瘤患者总生存的真实世界数据进行分析。
Oncologist. 2016 Nov;21(11):1355-1361. doi: 10.1634/theoncologist.2016-0104. Epub 2016 Aug 2.
9
Multiple myeloma: patient outcomes in real-world practice.多发性骨髓瘤：真实世界实践中的患者结局
Br J Haematol. 2016 Oct;175(2):252-264. doi: 10.1111/bjh.14213. Epub 2016 Jul 13.
10
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.统一临床试验报告的共识建议：国际骨髓瘤工作组共识小组报告 1.
Blood. 2011 May 5;117(18):4691-5. doi: 10.1182/blood-2010-10-299487. Epub 2011 Feb 3.